Kirby Institute at UNSW, Friday July 2nd, 2021 New research from the Kirby Institute at UNSW Sydney shows that HIV transmissions are at historically low rates among almost 10,000 high-risk gay and bisexual men on pre-exposure prophylaxis (PrEP), the HIV prevention medication. Low HIV rates persisted after PrEP moved from being available cost-free as part of a NSW clinical trial, to being...
Information about TRUVADA and ATRIPLA delisting
Australian Federation of AIDS Organisations (AFAO), March 30th 2020 From 1 April 2020 Truvada for HIV treatment and for pre-exposure prophylaxis (PrEP) will no longer be available through the Pharmaceutical Benefits Scheme (PBS). There are alternatives to Truvada for PrEP in Australia. Community members eligible for PrEP can access generic versions of Truvada supplied by Apotex, Mylan and Lupin...
Expanded HIV PrEP implementation in communities in NSW (EPIC-NSW): design of an open label, single arm implementation trial
BMC Public Health Published: 2 February 2018 Abstract: Background The New South Wales (NSW) HIV Strategy 2016–2020 aims for the virtual elimination of HIV transmission in NSW, Australia, by 2020. Despite high and increasing levels of HIV testing and treatment since 2012, the annual number of HIV diagnoses in NSW has remained generally unchanged. Pre-exposure prophylaxis (PrEP) is highly...
Australia’s biggest study on the use of HIV prevention treatment begins
Star Observer, 26 Nov 2014
If massively reducing your chances of contracting a chronic virus was as simple as regularly popping a pill, would you take your daily dose?
That’s the question researchers from the University of NSW’s Kirby Institute will be asking 300 HIV-negative men over the next two years.
Read more here
Find out more about the PrELUDE Study here